Tsai-hsien L. Hung

Linkou Branch
Taoyuan, TNQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

High Expression of SSEA3 and Globo H Predicts Poor Outcomes in Resected Extrahepatic Cholangiocarcinoma: A Single-Center Retrospective Cohort Study.

High Expression of SSEA3 and Globo H Predicts Poor Outcomes in Resected Extrahepatic Cholangiocarcinoma: A Single-Center Retrospective Cohort Study.

Journal: Cancer medicine

Published: May 26, 2026

Response to: "Clearing the fog, but not the entire picture: Elastase pretreatment for ALK FISH in lung cancer".

Response to: "Clearing the fog, but not the entire picture: Elastase pretreatment for ALK FISH in lung cancer".

Journal: Biomedical journal

Published: March 16, 2026

Globo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway.

Globo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway.

Journal: Theranostics

Published: September 30, 2025

Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability.

Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability.

Journal: Cancer gene therapy

Published: July 24, 2025

Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma.

Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: May 22, 2025

PufA drives cholangiocarcinoma progression via NFκB signaling activation: a novel therapeutic target.

PufA drives cholangiocarcinoma progression via NFκB signaling activation: a novel therapeutic target.

Journal: Cancer gene therapy

Published: May 12, 2025

YULINK deficiency promotes cell death under glucose restriction in HCC cells in association with GLUT1-mediated glycolysis.

YULINK deficiency promotes cell death under glucose restriction in HCC cells in association with GLUT1-mediated glycolysis.

Journal: Molecular medicine (Cambridge, Mass.)

Published: March 18, 2025

ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling.

ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling.

Journal: The Journal of biological chemistry

Published: February 06, 2025

Collagenase type IV improves the quality of HER2 fluorescence in situ hybridization for breast cancers.

Collagenase type IV improves the quality of HER2 fluorescence in situ hybridization for breast cancers.

Journal: American journal of clinical pathology

Published: January 23, 2025

Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion.

Tumor-Associated Glycan Exploits Adenosine Receptor 2A Signaling to Facilitate Immune Evasion.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)

Published: December 09, 2024

Elastase reduces background autofluorescence in ALK fluorescence in situ hybridization assays for lung cancers.

Elastase reduces background autofluorescence in ALK fluorescence in situ hybridization assays for lung cancers.

Journal: Biomedical journal

Published: November 09, 2024

Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer.

Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer.

Journal: Heliyon

Published: August 04, 2024

Showing 1-12 of 31

Last Updated: 09/26/2026